Seltorexant
Appearance
Clinical data | |
---|---|
Other names | MIN-202; JNJ-42847922; JNJ-922 |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C21H22FN7O |
Molar mass | 407.443 g/mol g·mol−1 |
3D model (JSmol) | |
|
Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).[1][2][3] As of December 2015, it is in phase II clinical trials for both insomnia and MDD.[2][4][5]
See also
References
- ^ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.
- ^ a b Zisapel, Nava (2014). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs: 1–11. doi:10.1517/13543784.2015.987340. ISSN 1354-3784.
- ^ Cristoph Boss; Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
- ^ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.
Further reading
- Discovery of JNJ-42847922, a Selective Orexin-2 Antagonist for the Treatment of Insomnia Disorder (see MEDI 244)
- Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia (page A3)
External links
Template:Signaling peptide/protein receptor modulators